MKI67 and adrenal cortex carcinoma: Further support for adjuvant mitotane came from another recent retrospective study that included 152 patients with non-metastatic ACC (100 patients who received adjuvant mitotane and 52 who did not receive adjuvant therapy) who were stratified by disease stage (I-II vs III), hormone secretion (yes vs. no), and Ki-67 index.